While protein levels of MAP2 do not change significantly in AD, its immunoreactivity in rat neuronal cell cultures has been shown to increase in response to serum from AD patients, particularly at 48 h post-application (Brewer and Ashford, 1992). The gene discussed is MAP2; the disease is Alzheimer disease.